Sociedad Americana de Hirudoterapia

Ministerio de Salud Pública del Uruguay — Departamento de Tecnología Médica

Uruguay MSP · Uruguay · latin america

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Uruguay's Ministry of Public Health, Department of Medical Technology — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national pharmaceutical and medical device framework as appropriate.

Regulatory Profile

Agency type
national regulator
Region
latin america
Country
Uruguay
Leech status
unregulated
Last ASH review
2026-05-27

Relevant Regulation Codes

  • Uruguayan Decreto-Ley 15.443 on medicinal products
  • Uruguayan national medical device regulatory framework
  • Mercosur harmonised pharmaceutical and medical device frameworks (where applicable)

Prescriber Requirements

  • Uruguayan Colegio Médico–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

MSP registration as applicable; Spanish-language labelling required by national law. Standard cold-chain conditions.

Import/Export Rules

MSP and Ministry of Livestock, Agriculture, and Fisheries clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana. Mercosur customs procedures apply.

Reimbursement Context

Fondo Nacional de Recursos (FNR) and Sistema Nacional Integrado de Salud (SNIS) coverage depends on inpatient bundling; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. Uruguay shares elements of pharmaceutical and device regulation with the Mercosur partners (Argentina ANMAT, Brazil ANVISA, Paraguay DNVS).

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.